The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …

The microbiome plays a key role in health and disease, and there has been considerable
interest in therapeutic targeting of the microbiome as well as mining this rich resource in …

Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion
(ADME) processes of a drug. Understanding PK properties is essential for drug development …

Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug
development and the pharmaceutical industry and regulatory authorities. Implementation of …

The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …

Solute carrier (SLC) transporters present as the loci of important drug–drug interactions
(DDIs). Therefore, sponsors generate in vitro half‐maximal inhibitory concentration (IC50) …

Cancer patients have an increased risk of developing venous thromboembolic events.
Anticoagulation management includes prophylactic or therapeutic doses of low molecular …

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-
tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or …

ABSTRACT Introduction Adverse drug reactions (ADRs) are among the leading causes of
death, and frequently associated with drug–gene interactions (DGIs). In addition to …

During new drug development, clinical drug interaction studies are carried out in
accordance with the mechanism of potential drug interactions evaluated by in vitro studies …